Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The approval of Lurcatinib cream marks a significant opportunity in the vitiligo market, being the first and only targeted therapy approved in China for this condition [7] - Clinical trials have shown positive results, with a significant percentage of patients achieving at least a 75% improvement in facial vitiligo area score after 24 weeks of treatment [7] - The company is also pursuing additional indications for Lurcatinib cream, including atopic dermatitis, which could further enhance its market potential [7] Financial Forecast and Valuation - Revenue projections for the company are as follows: 2023: 8,013 million RMB, 2024: 7,469 million RMB, 2025: 8,166 million RMB, 2026: 9,628 million RMB, and 2027: 12,069 million RMB, with growth rates of -12.4%, -6.8%, 9.3%, 17.9%, and 25.4% respectively [6] - Net profit forecasts are: 2023: 2,401 million RMB, 2024: 1,620 million RMB, 2025: 1,681 million RMB, 2026: 1,942 million RMB, and 2027: 2,333 million RMB, with growth rates of -26.3%, -32.5%, 3.8%, 15.6%, and 20.1% respectively [6] - The estimated reasonable market value for the company in 2026 is 677 billion HKD, based on a combination of price-to-earnings and price-to-sales ratios [7]
康哲药业（00867）：芦可替尼乳膏获批上市，掘金白癜风市场：康哲药业（00867.HK）